about
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulationAssociation of CYP3A5 genotypes with blood pressure and renal function in African familiesNonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.Can valproic acid be an inducer of clozapine metabolism?Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.Identification of a novel splice-site mutation in the CYP1A2 geneWeighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursCYP3A5 and ABCB1 genes and hypertension.Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population.The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution.Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.Blood pressure in relation to coffee and caffeine consumption.Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.Time course of response to paroxetine: influence of plasma level.Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.Prevalence of methadone injection in three Swiss cities.Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.Association of genetic risk scores with body mass index in Swiss psychiatric cohorts.Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study.Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments.Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.Lack of association between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population.The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
P50
Q28266466-48CC3C06-9C90-48CE-B17D-45F7700DC710Q28306953-8F853385-78E3-4FD9-BCEC-786A63158122Q30939231-34A4BBFC-0D29-425D-80E3-B5D33F1E39D1Q34209573-C1975598-1915-4F4A-9F09-7A194028DC7AQ34327769-DDE0BEAD-348C-4243-A798-2E0CAF5CD7B7Q34382951-DCACA5E0-E929-41DD-8808-3A31220608BFQ34497477-A4AE69D0-C065-40BB-B2E1-B75554E86680Q34510284-4FE947C6-2B25-4341-8E57-EB595BA2A71FQ34809340-4EAAAABD-F52A-492C-84BB-AC4FDE81A1C9Q35804713-9A8EDDBE-9DE7-4B29-BAAD-765B738C69BCQ35823299-47702AC2-03F3-48DE-AEC4-286D364272D5Q35825664-9E2521D4-FB22-4612-8795-E146E331D62CQ36176018-40336A9A-B17F-4D14-9692-120D8DC550B2Q36582619-43A75BE8-803D-4A76-B084-427BC048D183Q36729934-7F9588FA-FD88-494D-93CE-B1EA7A35F748Q37416133-E0D49038-A4EC-418C-ABDF-FE9D0096B706Q37419707-EA4BE534-0320-48B5-8A78-6EF3A6015811Q37760941-0FB4AC7A-C51A-48E4-B48A-570DEFB6704BQ38160338-55EEAD56-7114-4CEF-B19A-76CC6E36E60BQ38236743-D9DBCB22-FF77-49EE-A97A-A3583F04CA1EQ38305749-203D9BF1-DEF1-4B89-A0B0-C3F79AA589A8Q39291645-EB21F37D-9073-461A-90FC-D3920FB9DE25Q39337612-F01E440A-54CD-48CE-87B6-35E28A3BB0F0Q39664335-4313BB26-4812-4A91-B0B1-EA5C8930BAF1Q39726702-FFA129F4-0FBF-4AB3-8A43-F195599B3DD2Q39959563-E43F427E-BC94-47C5-A666-6345AF150F2CQ40034715-7FB81D4A-4678-4C41-97D8-536137C4E2E1Q40128463-E7ABFB9F-14C3-4652-8515-78D66A9C113CQ40233499-B2BB9362-D2BA-40EC-AD40-03C6B1448431Q40554461-F198822F-B921-44F6-849C-3855392A916AQ40780592-D182FEFB-6BC3-4C61-9C44-4A3081C14C33Q40839651-C9AE9E42-C362-443B-B573-506BBFBA8B83Q40885533-F437C46D-488D-4B1F-BA3F-76295AB2BDE4Q40955809-22FF985B-E942-4AC3-A476-6CE8C12708ECQ41111642-DF870C28-85DA-43A1-BE71-9073547AC811Q41254322-36FDEAF6-29CB-4272-AECB-C51FF39824D9Q41476590-653524F1-58A8-43FD-8569-2CE95BE3B1BDQ42711762-EFD9662A-F8FF-4AB6-8CF3-3D71497293C9Q42877968-D6E7F42E-C18A-4FB0-AE23-A48B57C8AC8EQ43267412-F7E47B62-4568-48A5-BF45-9E07F0B93EDF
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Chin B Eap
@es
Chin B. Eap
@en
Chin B. Eap
@nl
Chin B. Eap
@sl
type
label
Chin B Eap
@es
Chin B. Eap
@en
Chin B. Eap
@nl
Chin B. Eap
@sl
prefLabel
Chin B Eap
@es
Chin B. Eap
@en
Chin B. Eap
@nl
Chin B. Eap
@sl
P214
P106
P1153
7006152937
P21
P213
0000 0003 5360 8928
P214
P2798
P31
P496
0000-0002-5439-0230
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-305955557